Impaired lymphocyte transformation in leukemic patients after intensive therapy.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003036:Cobalt Isotopes / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology* / Q000532:radiotherapy; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000528:radiation effects; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008934:Mitogens / Q000494:pharmacology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011830:Radiation Effects; D012075:Remission, Spontaneous / Q000276:immunology; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003036:Cobalt Isotopes; D008934:Mitogens; D003561:Cytarabine; D014316:Tritium; D008466:Mechlorethamine; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D013936:Thymidine; D008727:Methotrexate